FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

December 27, 2021

Study Completion Date

December 27, 2021

Conditions

Hemophilia A or B With Inhibitors

Interventions

BIOLOGICAL

FEIBA

Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate \[APCC\]), FEIBA NF.

Trial Locations (3)

PHI Institute for Transfusion Medicine of Macedonia, Skopje

MV Sklifosovskyi Poltava Hematology, Poltava

University Hospital Center Zagreb, Zagreb

All Listed Sponsors

collaborator

Baxalta Innovations GmbH, now part of Shire

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT02764489 - FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) | Biotech Hunter | Biotech Hunter